TABLE 4.

Comparing clinical changes between the intervention and control groups.

Symptoms (frequency per day)	Pomegranate (n = 32)	Placebo (n = 32)	p-value a
Daily breath shortness
Baseline	2.00 (0.00–3.00)	1.00 (0.00–2.00)	0.198
Endpoint (8 weeks)	0.00 (0.00–0.00)	1.00 (0.00–2.00)	0.001
Changes	−1.00 (−3.00) to (0.00)	0.00 (−1.00) to (1.00)	<0.001
p-value**	<0.001	0.791
Nocturnal breath shortness
Baseline	0.00 (0.00–1.00)	0.00 (0.00–1.75)	0.921
Endpoint (8 weeks)	0.00 (0.00–0.00)	0.00 (0.00–2.00)	0.003
Changes	0.00 (−1.00) to (0.00)	0.00 (0.00) to (0.00)	0.034
p-value**	0.002	0.821
Nocturnal waking up Baseline	0.00 (0.00–1.00)	0.00 (0.00–0.75)	0.400
Endpoint (8 weeks)	0.00 (0.00–0.00)	0.00 (0.00–0.00)	0.188
Changes	0.00 (−1.00) to (0.00)	0.00 (0.00) to (0.00)	0.028
p-value**	0.002	0.834
Limitation of asthma-related activity symptoms
Baseline	0.00 (0.00–1.00)	0.50 (0.00–2.00)	0.222
Endpoint (8 weeks)	0.00 (0.00–0.00)	0.00 (0.00–2.75)	0.003
Changes	0.00 (−1.00) to (0.00)	0.00 (0.00) to (0.00)	0.032
p-value**	0.003	0.991
Consumption of salbutamol spray
Baseline	0.00 (0.00–0.00)	0.00 (0.00–0.00)	0.601
Endpoint (8 weeks)	0.00 (0.00–0.00)	0.00 (0.00–0.00)	0.536
Changes	0.00 (0.00) to (0.00)	0.00 (0.00) to (0.00)	0.222
p-value**	0.172	0.280

^a Mann–Whitney U test ** Wilcoxon test. Values have been expressed as median (25th, 75th percentiles).